Anika Therapeutics, Inc. — Q3 2021 Form 10-Q Summary
Business Context and Reporting Period
Anika is a global joint-preservation company focused on osteoarthritis pain management, regenerative solutions, soft-tissue repair, and bone-preserving joint technologies. The company operates as one reportable segment and includes the Parcus Medical and Arthrosurface acquisitions completed in early 2020.
This unaudited filing covers the three and nine months ended September 30, 2021, compared with the same periods in 2020. The company had 14.4 million shares outstanding as of October 25, 2021.
Financial Results and Key Metrics
| Metric | Q3 2021 | Q3 2020 | 9M 2021 | 9M 2020 |
|---|---|---|---|---|
| Revenue | $39.5 million | $31.7 million | $112.0 million | $97.8 million |
| Gross profit | $23.0 million | $17.3 million | $64.8 million | $52.3 million |
| Gross margin | 58% | 55% | 58% | 53% |
| Operating income (loss) | $1.3 million | $(7.9) million | $11.7 million | $(10.4) million |
| Net income (loss) | $0.6 million | $(6.4) million | $9.9 million | $(8.3) million |
| Diluted EPS | $0.04 | $(0.45) | $0.68 | $(0.59) |
| Adjusted EBITDA | $5.7 million | $4.9 million | $16.6 million | $20.0 million |
- Q3 revenue increased 25%; nine-month revenue increased 15%.
- Joint Pain Management revenue increased 42% in Q3 and 6% year to date. Joint Preservation and Restoration revenue decreased 4% in Q3 but increased 35% year to date.
- Research and development expense increased 47% in Q3 and 35% year to date, primarily for product development, the Cingal pilot study, and European post-market studies.
- Selling, general and administrative expense increased 10% in Q3 and 20% year to date due to higher commercial activity, marketing, acquisition-related period comparisons, and stock-based compensation.
- Q3 and nine-month results included a $3.5 million and $21.9 million reduction, respectively, in the fair value of contingent consideration, benefiting operating income. The filing attributes the reductions primarily to lower expected achievement of certain milestones.
- Adjusted gross margin was 66% in Q3 and 69% for the first nine months, compared with 70% and 67%, respectively, in the prior-year periods.
Cash Flow, Liquidity, Debt, and Balance Sheet
- Cash and cash equivalents were $91.0 million at September 30, 2021, compared with $95.8 million at December 31, 2020. The company had no available-for-sale investments at September 30, 2021.
- Working capital was $137.0 million at September 30, 2021, compared with $140.5 million at year-end 2020.
- Operating cash flow was $3.9 million for the first nine months of 2021, down from $10.5 million in the prior-year period, primarily reflecting collection timing, tax payments, contingent consideration changes, and acquisition-related cash costs.
- Investing cash outflow was $1.9 million, including $4.0 million of capital expenditures, versus $88.1 million in 2020 when the acquisitions were funded.
- Financing cash outflow was $6.8 million, including $7.2 million classified as financing-related contingent consideration payments. The 2020 comparison included $50.0 million of long-term debt proceeds and $25.4 million of debt repayments.
- The September 30, 2021 balance sheet does not show a separate long-term debt balance; lease liabilities totaled $19.6 million, and contingent consideration totaled $3.5 million, all classified as current.
- Total assets were $352.9 million and stockholders’ equity was $290.1 million at September 30, 2021.
Material Changes, Outlook, and Risks
- Results improved from the pandemic-affected 2020 period as elective procedures and customer ordering partially recovered, particularly in the United States. Management cautions that COVID-19 variants, renewed restrictions, procedure cancellations, supply-chain conditions, and clinical-study delays could materially affect future results.
- The company completed launch activities for the WristMotion Total Wrist Arthroplasty System and received 510(k) clearance for Tactoset Injectable Bone Substitute for hardware augmentation.
- No goodwill impairment was recorded in 2021; a $18.1 million impairment charge was recorded in Q1 2020.
- Product rationalization charges of $2.1 million were recorded during the first nine months of 2021. Acquisition-related amortization and inventory fair-value step-up continued to reduce reported gross profit.
- Remaining contingent consideration was $3.5 million at September 30, 2021. The company had potential earn-out milestones totaling up to $100 million under the acquisition agreements, subject to achievement conditions; the recorded liability reflects management’s then-current fair value estimate.
- On October 21, 2021, former Parcus Medical unitholders filed an arbitration request concerning earn-out provisions. The company cannot estimate the potential liability and intends to defend the claims.
- The filing provides no formal revenue, earnings, or margin guidance. Management expects cash, operating resources, and available capital to fund requirements, but states that additional debt or equity financing could be required if resources become insufficient.
- Management reported effective disclosure controls and no material changes in internal control over financial reporting.
Important Facts for Investors to Verify
- Determine the sustainability of revenue recovery after COVID-19, particularly for Joint Preservation and Restoration products and the company’s dependence on elective procedures.
- Assess concentration risk: DePuy Synthes Mitek represented 51% of Q3 revenue and 46% of nine-month revenue.
- Separate recurring operating performance from the significant contingent-consideration fair-value benefit and other non-GAAP adjustments.
- Review cash conversion, working-capital movements, capital expenditures, and the absence of a separately presented long-term debt balance.
- Monitor the Parcus arbitration, remaining acquisition earn-outs, regulatory milestones, and potential future contingent payments.
- Evaluate the effect of increased R&D, commercial spending, stock-based compensation, acquisition amortization, and product rationalization on future margins and adjusted results.